Advertisement


Timothy J. Whelan, MD: When Can Radiotherapy Be Avoided After Breast-Conserving Surgery?

2022 ASCO Annual Meeting

Advertisement

Timothy J. Whelan, MD, of McMaster University and Hamilton Health Sciences, discusses findings from the LUMINA study, which found that women aged 55 or older who had grade 1–2 T1N0 luminal A breast cancer following breast-conserving surgery and were treated with endocrine therapy alone had very low rates of local tumor recurrence at 5 years. These patients, the research suggests, may be able to forgo radiotherapy (Abstract LBA501).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Women with breast cancer, early stage breast cancer, are primarily treated with lumpectomy, often endocrine therapy and radiation. And for many years now we've realized that the risk of local recurrence after lumpectomy has been steadily decreasing, and this has been attributed to smaller screen detected cancers, better surgical therapies and better systemic therapy. And radiation itself is associated with significant side effects, both early, such as fatigue and skin irritation, and late side effects such as breast distortion, which can affect cosmesis and quality of life. And rare life threatening side effects such as cardiac disease and second cancers. The question is arisen, can we avoid radiotherapy in women who are already going to have lumpectomy and endocrine therapy? We've done a number of studies which have evaluated clinical pathological factors alone, but haven't been able to identify a very low risk group of patients after lumpectomy and endocrine therapy alone. But over the last two decades, we realized a better understanding of the molecular biology of breast cancer and have identified four major intrinsic subtypes of breast cancer. Luminal A being the most common subtype and also the lowest risk subtype. The objective of our study was to determine women with clinical pathological factors, low risk and the Luminal A subtype who were treated with lumpectomy and endocrine therapy alone. Could they avoid radiotherapy? The Luminal was a prospective cohort study where we followed 500 women who had low clinical risk factors and Luminal A subtype determined by ER, PR, HER2 and a low Ki-67, less than 13.25%, which was measured centrally in three labs using the international working group methods. And we found over five years that women had a very low rate of local recurrence, only 2.3% with the upper border of the 90% confidence interval being 3.8%, which was well below the 5% limit that we had set for ourselves. We believe that this rate is very low and constitutes that we could omit radiotherapy in this low risk subtype. Should point out that the risk of contralateral breast cancer in this group of women was only 1.8%. Very similar to the risk of local recurrence and the risk of any recurrence was only 2.7%. Again, a low risk group of patients. Based on these results in women who meet the clinical criteria for the study, and I'll mention again, they were women less than or equal to 50 or greater than or equal to 55 years of age who had a T1 N0 cancer, grades 1 and 2, and the luminal A subtype as we determined who were treated with endocrine therapy, they can avoid radiotherapy. Now, although Luminal A is a common subtype, we estimate that this group of women probably constitutes about 10 to 15% of all women with breast cancer. Given that the risk of invasive breast cancer is about 300,000 annually per year in North America, we estimate that this would relate to about 30 to 40,000 women per year.

Related Videos

Head and Neck Cancer
Supportive Care

Carryn M. Anderson, MD, on Head and Neck Cancer: New Data on Avasopasem Manganese for Oral Mucositis

Carryn M. Anderson, MD, of the University of Iowa Hospital, discusses phase III results of the ROMAN trial of avasopasem manganese for patients with severe oral mucositis who are receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer. Compared with placebo, avasopasem manganese improved severe oral mucositis (Abstract 6005).

Breast Cancer

Ann H. Partridge, MD, MPH, and Kevin Kalinsky, MD, on Breast Cancer: Latest Findings on Fulvestrant or Exemestane With or Without Ribociclib

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Kevin Kalinsky, MD, of Winship Cancer Institute at Emory University, discuss phase II findings from the MAINTAIN trial, which showed a benefit in progression-free survival for patients with hormone receptor–positive/HER2-negative metastatic breast cancer when they switched to endocrine therapy and received ribociclib after disease progression on another CDK4/6 inhibitor (Abstract LBA1004).

Pancreatic Cancer

Pamela L. Kunz, MD, on Pancreatic Neuroendocrine Tumors: A Final Analysis of Temozolomide or Temozolomide Plus Capecitabine

Pamela L. Kunz, MD, of the Yale University School of Medicine, discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates with temozolomide plus capecitabine reported to date for patients with pancreatic neuroendocrine tumors. The presence of a deficiency of MGMT, the drug-resistance gene, was associated with greater odds of an objective response (Abstract 4004).

Breast Cancer

Etienne Brain, MD, PhD, on Breast Cancer: Adjuvant Endocrine Therapy With or Without Chemotherapy in Older Patients

Etienne Brain, MD, PhD, of the Institut Curie, discusses phase III findings from the Unicancer ASTER 70s trial, in which patients aged 70 or older with estrogen receptor–positive, HER2-negative breast cancer and a high genomic grade index received adjuvant endocrine therapy with or without chemotherapy. The data did not find a statistically significant overall survival benefit with this treatment after surgery (Abstract 500).

Gynecologic Cancers

Ursula A. Matulonis, MD, and Domenica Lorusso, MD, PhD, on Gynecologic Cancers: New Findings on Trabectedin vs Clinician’s Choice Chemotherapy

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Domenica Lorusso, MD, PhD, of Italy’s Gemelli University Hospital, discuss phase III data from the MITO23 trial on single-agent trabectedin vs clinician’s choice of chemotherapy in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype. Although trabectedin has demonstrated antitumor activity in relapsed platinum-sensitive disease, it does not appear to improve survival outcomes when compared with standard chemotherapy in the BRCA-mutated population (Abstract LBA5504).

Advertisement

Advertisement




Advertisement